Cellectis (CLLS) Non-Current Assets (2014 - 2026)
Cellectis (CLLS) recorded quarterly Non-Current Assets of $84.6 million in Q1 2026, down 4.34% quarter-over-quarter from $88.5 million in Q4 2025, and down 8.26% on a YoY basis from $92.3 million in Q1 2025.
Cellectis (CLLS) Non-Current Assets (2014 - 2026) Analysis & Trends
Cellectis' Non-Current Assets history runs 13 years deep, the most recent figure standing at $84.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.26% year-over-year to $84.6 million; the TTM figure through Mar 2026 stood at $84.6 million (down 8.26% YoY), while the FY2025 annual figure was $88.5 million, down 8.29% from the prior year.
- Non-Current Assets was $84.6 million for Q1 2026 at Cellectis, down from $88.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $152.0 million in Q1 2022 to a low of $84.6 million in Q1 2026.
- Historically, Non-Current Assets has averaged $112.0 million across 5 years, with a median of $113.2 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets fell 25.05% in 2022, then grew 21.69% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $117.4 million in 2022, then slipped by 13.75% to $101.3 million in 2023, then retreated by 4.73% to $96.5 million in 2024, then declined by 8.29% to $88.5 million in 2025, then declined by 4.34% to $84.6 million in 2026.
- The last three Non-Current Assets figures came in at $84.6 million (Q1 2026), $88.5 million (Q4 2025), and $121.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 84.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.64 Mn |
| Dec 31, 2025 | 88.48 Mn |
| Sep 30, 2025 | 121.85 Mn |
| Jun 30, 2025 | 123.33 Mn |
| Mar 31, 2025 | 92.26 Mn |
| Dec 31, 2024 | 96.48 Mn |
| Sep 30, 2024 | 101.45 Mn |
| Jun 30, 2024 | 101.34 Mn |
| Mar 31, 2024 | 96.39 Mn |
| Dec 31, 2023 | 101.27 Mn |
| Sep 30, 2023 | 113.21 Mn |
| Jun 30, 2023 | 114.39 Mn |
| Mar 31, 2023 | 114.04 Mn |
| Dec 31, 2022 | 117.41 Mn |
| Sep 30, 2022 | 139.31 Mn |
| Jun 30, 2022 | 145.72 Mn |
| Mar 31, 2022 | 152.02 Mn |
| Dec 31, 2021 | 156.65 Mn |
| Sep 30, 2021 | 177.04 Mn |
| Jun 30, 2021 | 177.21 Mn |